In a trial study, Zaltrap was tested on 1,226 patients with colorectal cancer that had metastasized. All the patients had been treated with Eloxatin, an older Sanofi drug, before the trial.
Zaltrap is designed to block compounds that help tumors grow new blood vessels and are linked to inflammation. Side effects include diarrhea, fatigue, inflammation of the mucus membranes of the mouth, infections, high blood pressure, gastrointestinal pains and low white blood cell count.
Read the Bloomberg Business Week report on Zaltrap.
Related Articles on Colon Cancer:
Study: New Biopsy Needle Accurately Diagnoses Cancers of GI Tract
Study: Folic Acid May Protect Pregnant Mothers’ Offspring From Colon Cancer
Office Desk Jobs Double Colon Cancer Risk
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
